Literature DB >> 16268668

Rotigotine: a viewpoint by Peter LeWitt.

Peter LeWitt1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16268668     DOI: 10.2165/00023210-200519110-00008

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  8 in total

1.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

2.  Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.

Authors:  J T Hutton; L V Metman; T N Chase; J L Juncos; W C Koller; R Pahwa; P A LeWitt; A Samii; J K Tsui; D B Calne; C H Waters; V P Calabrese; J P Bennett; R Barrett; J L Morris
Journal:  Mov Disord       Date:  2001-05       Impact factor: 10.338

3.  Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

Authors:  L V Metman; M Gillespie; C Farmer; F Bibbiani; S Konitsiotis; M Morris; H Shill; W Bara-Jimenez; M M Mouradian; T N Chase
Journal:  Clin Neuropharmacol       Date:  2001 May-Jun       Impact factor: 1.592

4.  Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.

Authors:  Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Jean-Paul Nicolas; Frédéric De Ceuninck; Jean-A Boutin; Mark J Millan
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

5.  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.

Authors: 
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

6.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

7.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.

Authors:  Alan L Whone; Ray L Watts; A Jon Stoessl; Margaret Davis; Sven Reske; Claude Nahmias; Anthony E Lang; Olivier Rascol; Maria J Ribeiro; Philippe Remy; Werner H Poewe; Robert A Hauser; David J Brooks
Journal:  Ann Neurol       Date:  2003-07       Impact factor: 10.422

8.  Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Authors:  Robert G Holloway; Ira Shoulson; Stanley Fahn; Karl Kieburtz; Anthony Lang; Kenneth Marek; Michael McDermott; John Seibyl; William Weiner; Bruno Musch; Cornelia Kamp; Mickie Welsh; Aileen Shinaman; Rajesh Pahwa; Lynn Barclay; Jean Hubble; Peter LeWitt; Janis Miyasaki; Oksana Suchowersky; Mark Stacy; David S Russell; Blair Ford; John Hammerstad; David Riley; David Standaert; Frederick Wooten; Stewart Factor; Joseph Jankovic; Farah Atassi; Roger Kurlan; Michel Panisset; Ali Rajput; Robert Rodnitzky; Cliff Shults; Giselle Petsinger; Cheryl Waters; Ronald Pfeiffer; Kevin Biglan; Leona Borchert; Amy Montgomery; Laura Sutherland; Carolyn Weeks; Maryan DeAngelis; Elspeth Sime; Susan Wood; Carol Pantella; Mary Harrigan; Barbara Fussell; Sandra Dillon; Barbara Alexander-Brown; Pamela Rainey; Marsha Tennis; Elke Rost-Ruffner; Diane Brown; Sharon Evans; Debra Berry; Jean Hall; Theresa Shirley; Judith Dobson; Deborah Fontaine; Brenda Pfeiffer; Alicia Brocht; Susan Bennett; Susan Daigneault; Karen Hodgeman; Carolynn O'Connell; Tori Ross; Karen Richard; Arthur Watts
Journal:  Arch Neurol       Date:  2004-07
  8 in total
  1 in total

1.  Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation.

Authors:  J Kehr; X-J Hu; M Goiny; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2007-04-16       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.